chevron_leftBack
As of 6 June 2026, Aelis Farma S.A. has a market cap of $20.18M USD, ranking #37029 globally and #438 in France.
It ranks #3324 in the Healthcare sector, and #651 in the Biotechnology industry.
Key Stats
Market Cap
$20.18MUSD
17.37M EUR
Enterprise Value
$15.65MUSD
13.47M EUR
Revenue (TTM)
$2.71MUSD
2.33M EUR
EBITDA (TTM)
-$9.45MUSD
-8.13M EUR
Net Income (TTM)
-$9.52MUSD
-8.2M EUR
PS Ratio
7.4
PB Ratio
2.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Pier Piazza
open_in_new
Employees
24
Founded
2013
Website
aelisfarma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -0.2% | 0.6% | -34% | 9.7% | 4.3% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AELIS
Aelis Farma SA
ISIN: FR0014007ZB4
Shares Out.:
Shares Outstanding:
13.707M1
Shares Float:
4.162M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.25 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Aelis Farma S.A.
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EPA: VIRP
|
$3.56B
18K%
3.07B EUR
|
20.3
|
|
EPA: IVA
|
$1.01B
5K%
873.41M EUR
|
-
|
|
EPA: VLA
|
$487.18M
2K%
419.44M EUR
|
-
|
|
EPA: GNFT
|
$467.9M
2K%
402.84M EUR
|
-
|
|
EPA: TNG
|
$238.59M
1K%
205.41M EUR
|
-
|
|
EPA: EAPI
|
$150.36M
645%
129.46M EUR
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
904K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
792K%
|
19.0
|
|
EBR: ARGX
|
$48.08B
238K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
220K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
213K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.72B
212K%
33.71B CHF
|
37.2
|
chevron_leftBack